Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Interest in and Use of Smoking Cessation Support Across Pregnancy and Postpartum.

Naughton F, Vaz LR, Coleman T, Orton S, Bowker K, Leonardi-Bee J, Cooper S, Vanderbloemen L, Sutton S, Ussher M.

Nicotine Tob Res. 2019 Aug 23. pii: ntz151. doi: 10.1093/ntr/ntz151. [Epub ahead of print]

PMID:
31570944
2.

Comparative evaluation of eight in vitro pharmacodynamic models of infection: Activity of moxifloxacin against Escherichia coli and Streptococcus pneumoniae as an exemplary example.

Dalhoff A, Bowker K, MacGowan A.

Int J Antimicrob Agents. 2019 Sep 19. pii: S0924-8579(19)30256-0. doi: 10.1016/j.ijantimicag.2019.09.013. [Epub ahead of print]

PMID:
31542319
3.

Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-18.

Findlay J, Gould VC, North P, Bowker KE, Williams MO, MacGowan AP, Avison MB.

J Antimicrob Chemother. 2019 Sep 20. pii: dkz397. doi: 10.1093/jac/dkz397. [Epub ahead of print]

PMID:
31538190
4.

Pathways to optimising antibiotic use in rural China: identifying key determinants in community and clinical settings, a mixed methods study protocol.

Zhao L, Kwiatkowska RM, Chai J, Cabral C, Chen M, Bowker K, Coope C, Shen J, Shen X, Cheng J, Feng R, Kadetz P, MacGowan A, Oliver I, Hickman M, Wang D, Lambert H.

BMJ Open. 2019 Aug 10;9(8):e027819. doi: 10.1136/bmjopen-2018-027819.

5.

Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.

Noel AR, Attwood M, Bowker KE, Kim A, Krause KM, MacGowan AP.

Int J Antimicrob Agents. 2019 Nov;54(5):626-632. doi: 10.1016/j.ijantimicag.2019.07.001. Epub 2019 Jul 9.

PMID:
31299297
6.

Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures.

Noel AR, Bowker KE, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2019 Jul 1;74(7):1945-1951. doi: 10.1093/jac/dkz114.

PMID:
31220257
7.

Feasibility and Acceptability of 'Opt-In' Referrals for Stop Smoking Support in Pregnancy.

Campbell KA, Orton S, Bowker K, Cooper S, Coleman T.

Int J Environ Res Public Health. 2019 Apr 16;16(8). pii: E1358. doi: 10.3390/ijerph16081358.

8.

An in vitro biofilm model of Staphylococcus aureus infection of bone.

Sweeney E, Lovering AM, Bowker KE, MacGowan AP, Nelson SM.

Lett Appl Microbiol. 2019 Apr;68(4):294-302. doi: 10.1111/lam.13131. Epub 2019 Mar 13.

PMID:
30770577
9.

Attitudes to E-Cigarettes and Cessation Support for Pregnant Women from English Stop Smoking Services: A Mixed Methods Study.

Cooper S, Orton S, Campbell KA, Ussher M, Coleman-Haynes N, Whitemore R, Dickinson A, McEwen A, Lewis S, Naughton F, Bowker K, Sinclair L, Bauld L, Coleman T.

Int J Environ Res Public Health. 2019 Jan 3;16(1). pii: E110. doi: 10.3390/ijerph16010110.

10.

Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.

Noel AR, Bowker KE, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2018 Sep 1;73(9):2411-2417. doi: 10.1093/jac/dky225.

PMID:
30020472
11.

Views on and experiences of electronic cigarettes: a qualitative study of women who are pregnant or have recently given birth.

Bowker K, Orton S, Cooper S, Naughton F, Whitemore R, Lewis S, Bauld L, Sinclair L, Coleman T, Dickinson A, Ussher M.

BMC Pregnancy Childbirth. 2018 Jun 15;18(1):233. doi: 10.1186/s12884-018-1856-4.

12.

Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2018 May 1;73(5):1305-1313. doi: 10.1093/jac/dky002.

PMID:
29562340
13.

Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes.

Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Heesom KJ, Jiménez-Castellanos JC, Zhang J, Graham L, Bowker K, Williams OM, MacGowan AP, Avison MB.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01814-17. doi: 10.1128/AAC.01814-17. Print 2018 Mar.

14.

Smoking and quit attempts during pregnancy and postpartum: a longitudinal UK cohort.

Cooper S, Orton S, Leonardi-Bee J, Brotherton E, Vanderbloemen L, Bowker K, Naughton F, Ussher M, Pickett KE, Sutton S, Coleman T.

BMJ Open. 2017 Nov 15;7(11):e018746. doi: 10.1136/bmjopen-2017-018746.

15.

Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection.

Alfouzan WA, Noel AR, Bowker KE, Attwood MLG, Tomaselli SG, MacGowan AP.

Int J Antimicrob Agents. 2017 Dec;50(6):715-717. doi: 10.1016/j.ijantimicag.2017.06.026. Epub 2017 Jul 10.

PMID:
28705678
16.

The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.

MacGowan A, Tomaselli S, Noel A, Bowker K.

J Antimicrob Chemother. 2017 Mar 1;72(3):762-769. doi: 10.1093/jac/dkw480.

PMID:
28039276
17.

Antenatal Clinic and Stop Smoking Services Staff Views on "Opt-Out" Referrals for Smoking Cessation in Pregnancy: A Framework Analysis.

Campbell KA, Bowker KA, Naughton F, Sloan M, Cooper S, Coleman T.

Int J Environ Res Public Health. 2016 Oct 12;13(10). pii: E1004.

18.

'Opt-out' referrals after identifying pregnant smokers using exhaled air carbon monoxide: impact on engagement with smoking cessation support.

Campbell KA, Cooper S, Fahy SJ, Bowker K, Leonardi-Bee J, McEwen A, Whitemore R, Coleman T.

Tob Control. 2017 May;26(3):300-306. doi: 10.1136/tobaccocontrol-2015-052662. Epub 2016 May 25.

19.

Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, MacGowan AP.

J Antimicrob Chemother. 2016 May;71(5):1270-8. doi: 10.1093/jac/dkv480. Epub 2016 Feb 3.

PMID:
26846209
20.

Pregnant Women's Experiences and Views on an "Opt-Out" Referral Pathway to Specialist Smoking Cessation Support: A Qualitative Evaluation.

Sloan M, Campbell KA, Bowker K, Coleman T, Cooper S, Brafman-Price B, Naughton F.

Nicotine Tob Res. 2016 May;18(5):900-5. doi: 10.1093/ntr/ntv273. Epub 2016 Jan 6.

21.

Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.

MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.

22.

Adaptation and uptake evaluation of an SMS text message smoking cessation programme (MiQuit) for use in antenatal care.

Naughton F, Cooper S, Bowker K, Campbell K, Sutton S, Leonardi-Bee J, Sloan M, Coleman T.

BMJ Open. 2015 Oct 22;5(10):e008871. doi: 10.1136/bmjopen-2015-008871. Erratum in: BMJ Open. 2015;5(11):e008871corr1.

23.

Understanding Pregnant Smokers' Adherence to Nicotine Replacement Therapy During a Quit Attempt: A Qualitative Study.

Bowker K, Campbell KA, Coleman T, Lewis S, Naughton F, Cooper S.

Nicotine Tob Res. 2016 May;18(5):906-12. doi: 10.1093/ntr/ntv205. Epub 2015 Sep 21.

24.

The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.

Albur MS, Noel A, Bowker K, MacGowan A.

Int J Antimicrob Agents. 2015 Nov;46(5):560-7. doi: 10.1016/j.ijantimicag.2015.07.019. Epub 2015 Sep 5.

PMID:
26387065
25.

Changes in the rate of nicotine metabolism across pregnancy: a longitudinal study.

Bowker K, Lewis S, Coleman T, Cooper S.

Addiction. 2015 Nov;110(11):1827-32. doi: 10.1111/add.13029. Epub 2015 Aug 3.

26.

Prevalence of antibiotic resistance in Escherichia coli isolated from urine samples routinely referred by general practitioners in a large urban centre in south-west England.

Chin TL, MacGowan AP, Bowker KE, Elder F, Beck CR, McNulty C.

J Antimicrob Chemother. 2015 Jul;70(7):2167-9. doi: 10.1093/jac/dkv050. Epub 2015 Mar 11. No abstract available.

PMID:
25766735
27.

Longitudinal cohort survey of women's smoking behaviour and attitudes in pregnancy: study methods and baseline data.

Orton S, Bowker K, Cooper S, Naughton F, Ussher M, Pickett KE, Leonardi-Bee J, Sutton S, Dhalwani NN, Coleman T.

BMJ Open. 2014 May 14;4(5):e004915. doi: 10.1136/bmjopen-2014-004915. Erratum in: BMJ Open. 2015;5(11):e004915corr1.

28.

Comparison of cotinine levels in pregnant women while smoking and when using nicotine replacement therapy.

Bowker KA, Lewis S, Coleman T, Vaz LR, Cooper S.

Nicotine Tob Res. 2014 Jun;16(6):895-8. doi: 10.1093/ntr/ntu029. Epub 2014 Mar 15.

29.

Colistin susceptibility testing: time for a review.

Albur M, Noel A, Bowker K, Macgowan A.

J Antimicrob Chemother. 2014 May;69(5):1432-4. doi: 10.1093/jac/dkt503. Epub 2013 Dec 29. No abstract available.

PMID:
24379306
30.

Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Bowker KE.

Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6. doi: 10.1128/AAC.01386-12. Epub 2013 Mar 4.

31.

Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum.

Bowker KE, Garvey MI, Noel AR, Tomaselli SG, Macgowan AP.

J Antimicrob Chemother. 2013 May;68(5):1130-8. doi: 10.1093/jac/dks537. Epub 2013 Jan 29.

PMID:
23361641
32.

Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP.

Antimicrob Agents Chemother. 2012 Oct;56(10):5009-15. doi: 10.1128/AAC.06111-11. Epub 2012 Jun 19.

33.

Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae.

Albur M, Noel A, Bowker K, MacGowan A.

Antimicrob Agents Chemother. 2012 Jun;56(6):3441-3. doi: 10.1128/AAC.05682-11. Epub 2012 Mar 5.

34.

Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia.

Albur MS, Bowker K, Weir I, MacGowan A.

Eur J Clin Microbiol Infect Dis. 2012 Mar;31(3):295-301. doi: 10.1007/s10096-011-1310-2. Epub 2011 Jun 14.

PMID:
21667352
35.

Reducing the risk of surgical site infection: a case controlled study of contamination of theatre clothing.

Sivanandan I, Bowker KE, Bannister GC, Soar J.

J Perioper Pract. 2011 Feb;21(2):69-72.

PMID:
21476422
36.

Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K.

Antimicrob Agents Chemother. 2011 Apr;55(4):1436-42. doi: 10.1128/AAC.00936-10. Epub 2011 Jan 24.

37.

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.

Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.

38.

Cyanoacrylate dressings: are they microbiologically impermeable?

Rocos B, Blom AW, Bowker K.

J Hosp Infect. 2010 Jun;75(2):144-5. doi: 10.1016/j.jhin.2010.01.008. Epub 2010 Apr 24. No abstract available.

PMID:
20417580
39.

Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.

MacGowan AP, Reynolds R, Noel AR, Bowker KE.

Antimicrob Agents Chemother. 2009 Dec;53(12):5181-4. doi: 10.1128/AAC.00118-09. Epub 2009 Oct 5.

40.

Headwear in laminar flow operating theatres.

Gordon RJ, Bannister GC, Bowker KE, Mason AC, Cheung LL, Eames R.

J Hosp Infect. 2009 Nov;73(3):289-91. doi: 10.1016/j.jhin.2009.08.001. Epub 2009 Sep 26. No abstract available.

PMID:
19783069
41.

Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, MacGowan AP.

J Antimicrob Chemother. 2009 Nov;64(5):1044-51. doi: 10.1093/jac/dkp289. Epub 2009 Sep 16.

PMID:
19759041
42.

In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.

Bowker KE, Caspers P, Gaucher B, MacGowan AP.

Antimicrob Agents Chemother. 2009 Nov;53(11):4949-52. doi: 10.1128/AAC.00845-09. Epub 2009 Sep 8.

43.

Storage of equipment above areas used for opening sterile theatre gowns: is there an infection risk?

Pentlow A, Murray J, Bowker K.

J Hosp Infect. 2009 Oct;73(2):178-9. doi: 10.1016/j.jhin.2009.06.014. Epub 2009 Aug 28. No abstract available.

PMID:
19716200
44.

Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Macgowan AP.

Antimicrob Agents Chemother. 2008 Dec;52(12):4370-3. doi: 10.1128/AAC.00922-07. Epub 2008 Jun 2.

45.
46.

Theatre shoes - a link in the common pathway of postoperative wound infection?

Amirfeyz R, Tasker A, Ali S, Bowker K, Blom A.

Ann R Coll Surg Engl. 2007 Sep;89(6):605-8. doi: 10.1308/003588407X205440.

47.

Topical ethyl chloride fine spray. Does it have any antimicrobial activity?

Burney K, Bowker K, Reynolds R, Bradley M.

Clin Radiol. 2006 Dec;61(12):1055-7.

PMID:
17097428
48.

Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory.

Soltani M, Tobin CM, Bowker KE, Sunderland J, MacGowan AP, Lovering AM.

Int J Antimicrob Agents. 2006 Dec;28(6):574-7. Epub 2006 Nov 7.

PMID:
17085019
49.

Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.

Bowker KE, Noel AR, MacGowan AP.

J Antimicrob Chemother. 2006 Oct;58(4):802-5. Epub 2006 Aug 5.

PMID:
16891629
50.

Should finger rings be removed prior to scrubbing for theatre?

Kelsall NK, Griggs RK, Bowker KE, Bannister GC.

J Hosp Infect. 2006 Apr;62(4):450-2. Epub 2006 Feb 17.

PMID:
16487627

Supplemental Content

Loading ...
Support Center